Summary
2.71 -0.10(-3.39%)07/01/2024
Organogenesis Holdings Inc (ORGO)
Organogenesis Holdings Inc (ORGO)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -3.22 | 10.18 | 3.64 | -3.39 | -33.70 | -19.25 | -66.19 | -72.26 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 2.71 | |
| Open | 2.90 | |
| High | 2.90 | |
| Low | 2.70 | |
| Volume | 353,722 | |
| Change | -0.09 | |
| Change % | -3.22 | |
| Avg Volume (20 Days) | 317,204 | |
| Volume/Avg Volume (20 Days) Ratio | 1.12 | |
| 52 Week Range | 1.96 - 4.71 | |
| Price vs 52 Week High | -42.57% | |
| Price vs 52 Week Low | 38.01% | |
| Range | -6.72 | |
| Gap Up/Down | 0.06 | |
Fundamentals | ||
| Market Capitalization (Mln) | 358 | |
| EBIDTA | 84,991,000 | |
| PE Ratio | 20.1512 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 24.00 | |
| Book Value | 1.4710 | |
| Earnings Per Share | 0.4630 | |
| EPS Estimate Current Quarter | 0.0600 | |
| EPS Estimate Next Quarter | 0.0900 | |
| EPS Estimate Current Year | 0.4100 | |
| EPS Estimate Next Year | 0.4700 | |
| Diluted EPS (TTM) | 0.4630 | |
| Revenues | ||
| Profit Marging | 0.1395 | |
| Operating Marging (TTM) | 0.1694 | |
| Return on asset (TTM) | 0.1532 | |
| Return on equity (TTM) | 0.4888 | |
| Revenue TTM | 446,308,000 | |
| Revenue per share TTM | 3.5610 | |
| Quarterly Revenue Growth (YOY) | 0.1290 | |
| Quarterly Earnings Growth (YOY) | -0.5260 | |
| Gross Profit (TTM) | 250,979,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 20.1512 | |
| Forward PE | 18.8324 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 6.5691 | |
| Revenue Enterprise Value | 2.8065 | |
| EBITDA Enterprise Value | 14.4951 | |
| Shares | ||
| Shares Outstanding | 128,644,000 | |
| Shares Float | 55,834,326 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 51.31 | |
| Institutions (%) | 43.10 | |
06/06 16:05 EST - globenewswire.com
Organogenesis Holdings Inc. to Participate in the Truist Securities MedTech Conference
CANTON, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that management will participate in the Truist Securities MedTech Conference, which is being held at the InterContinental Boston in Boston, MA on Tuesday, June 18th. Management will participate in 1x1 meetings. There will be no formal presentation.
Organogenesis Holdings Inc. to Participate in the Truist Securities MedTech Conference
CANTON, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that management will participate in the Truist Securities MedTech Conference, which is being held at the InterContinental Boston in Boston, MA on Tuesday, June 18th. Management will participate in 1x1 meetings. There will be no formal presentation.
05/09 21:01 EST - seekingalpha.com
Organogenesis Holdings, Inc. (ORGO) Q1 2024 Earnings Call Transcript
Organogenesis Holdings, Inc. (NASDAQ:ORGO ) Q1 2024 Earnings Conference Call May 9, 2024 5:00 PM ET Company Participants Gary Gillheeney - President, Chief Executive Officer & Chair Dave Francisco - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Ross Osborn - Cantor Fitzgerald Drew Ranieri - Morgan Stanley Operator Welcome ladies and gentlemen to the First Quarter and Fiscal Year 2024 Earnings Conference Call for Organogenesis Holdings Inc. Please note, that this conference call is being recorded and the recording will be available on the company's website for replay shortly. Before we begin, I would like to remind everyone that our remarks today may contain forward-looking statements that are based on current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including the risks and uncertainties described in the company's filings with the Securities and Exchange Commission, including Item 1A, Risk Factors, of the company's most recent annual report and a sequential filing with quarterly reports.
Organogenesis Holdings, Inc. (ORGO) Q1 2024 Earnings Call Transcript
Organogenesis Holdings, Inc. (NASDAQ:ORGO ) Q1 2024 Earnings Conference Call May 9, 2024 5:00 PM ET Company Participants Gary Gillheeney - President, Chief Executive Officer & Chair Dave Francisco - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Ross Osborn - Cantor Fitzgerald Drew Ranieri - Morgan Stanley Operator Welcome ladies and gentlemen to the First Quarter and Fiscal Year 2024 Earnings Conference Call for Organogenesis Holdings Inc. Please note, that this conference call is being recorded and the recording will be available on the company's website for replay shortly. Before we begin, I would like to remind everyone that our remarks today may contain forward-looking statements that are based on current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including the risks and uncertainties described in the company's filings with the Securities and Exchange Commission, including Item 1A, Risk Factors, of the company's most recent annual report and a sequential filing with quarterly reports.
05/02 07:00 EST - globenewswire.com
Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis
CANTON, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that its Phase 3 randomized control trial evaluating the safety and efficacy of ReNu, a cryopreserved amniotic suspension allograft (ASA), for the management of symptoms associated with knee osteoarthritis (OA) achieved its primary endpoint upon the analysis of positive top line data.
Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis
CANTON, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that its Phase 3 randomized control trial evaluating the safety and efficacy of ReNu, a cryopreserved amniotic suspension allograft (ASA), for the management of symptoms associated with knee osteoarthritis (OA) achieved its primary endpoint upon the analysis of positive top line data.
04/16 07:30 EST - globenewswire.com
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024
CANTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that first quarter of fiscal year 2024 financial results will be reported after the market closes on Thursday, May 9th.
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024
CANTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that first quarter of fiscal year 2024 financial results will be reported after the market closes on Thursday, May 9th.
04/03 07:30 EST - globenewswire.com
Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case
CANTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ: ORGO) a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that on March 29, 2024, the United States District Court for the Eastern District of New York granted, with prejudice, the Company's motion to dismiss all claims asserted.
Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case
CANTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ: ORGO) a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that on March 29, 2024, the United States District Court for the Eastern District of New York granted, with prejudice, the Company's motion to dismiss all claims asserted.
03/01 18:29 EST - fool.com
Why Organogenesis Holding Stock Plummeted by 18% Today
To put it charitably, the market wasn't impressed with the company's recent performance. They traded out of the stock following the publication of quarterly and annual results.
Why Organogenesis Holding Stock Plummeted by 18% Today
To put it charitably, the market wasn't impressed with the company's recent performance. They traded out of the stock following the publication of quarterly and annual results.
02/29 23:06 EST - seekingalpha.com
Organogenesis Holdings, Inc. (ORGO) Q4 2023 Earnings Call Transcript
Organogenesis Holdings, Inc. (ORGO) Q4 2023 Earnings Call Transcript
Organogenesis Holdings, Inc. (ORGO) Q4 2023 Earnings Call Transcript
Organogenesis Holdings, Inc. (ORGO) Q4 2023 Earnings Call Transcript
02/29 18:46 EST - zacks.com
Organogenesis (ORGO) Reports Break-Even Earnings for Q4
Organogenesis (ORGO) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.06 per share a year ago.
Organogenesis (ORGO) Reports Break-Even Earnings for Q4
Organogenesis (ORGO) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.06 per share a year ago.
02/29 16:05 EST - globenewswire.com
Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance
CANTON, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2023.
Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance
CANTON, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2023.
02/12 07:30 EST - globenewswire.com
Organogenesis Holdings Inc. to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference
CANTON, Mass., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that management will participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference, which is being held at the Cliff Lodge in Snowbird, UT from February 13th-14th.
Organogenesis Holdings Inc. to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference
CANTON, Mass., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that management will participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference, which is being held at the Cliff Lodge in Snowbird, UT from February 13th-14th.
02/08 16:05 EST - globenewswire.com
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29, 2024
CANTON, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that fourth quarter and fiscal year 2023 financial results will be reported after the market closes on Thursday, February 29th.
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29, 2024
CANTON, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that fourth quarter and fiscal year 2023 financial results will be reported after the market closes on Thursday, February 29th.
01/15 13:32 EST - zacks.com
Are You Looking for a Top Momentum Pick? Why Organogenesis (ORGO) is a Great Choice
Does Organogenesis (ORGO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are You Looking for a Top Momentum Pick? Why Organogenesis (ORGO) is a Great Choice
Does Organogenesis (ORGO) have what it takes to be a top stock pick for momentum investors? Let's find out.
01/05 11:17 EST - zacks.com
Best Momentum Stocks to Buy for January 5th
ORGO, CALM and NET made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 5, 2024.
Best Momentum Stocks to Buy for January 5th
ORGO, CALM and NET made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 5, 2024.
01/05 08:16 EST - zacks.com
New Strong Buy Stocks for January 5th
ORGO, CALM, W, NET and EVH have been added to the Zacks Rank #1 (Strong Buy) List on January 5, 2024.
New Strong Buy Stocks for January 5th
ORGO, CALM, W, NET and EVH have been added to the Zacks Rank #1 (Strong Buy) List on January 5, 2024.
12/28 13:32 EST - zacks.com
Organogenesis (ORGO) is a Great Momentum Stock: Should You Buy?
Does Organogenesis (ORGO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Organogenesis (ORGO) is a Great Momentum Stock: Should You Buy?
Does Organogenesis (ORGO) have what it takes to be a top stock pick for momentum investors? Let's find out.
12/15 09:46 EST - zacks.com
5 Reasons Why Small-Cap Stocks Can Surge in 2024: 5 Top Picks
Small-cap stocks should rally ahead due to cheaper valuation, cooling inflation data and hopes of Fed rate cuts in 2024. Against this backdrop, Organogenesis (ORGO), Riskified (RSKD), Hooker Furniture Corporation (HOFT), Stoneridge (SRI) and VirTra (VTSI) emerge as winning picks.
5 Reasons Why Small-Cap Stocks Can Surge in 2024: 5 Top Picks
Small-cap stocks should rally ahead due to cheaper valuation, cooling inflation data and hopes of Fed rate cuts in 2024. Against this backdrop, Organogenesis (ORGO), Riskified (RSKD), Hooker Furniture Corporation (HOFT), Stoneridge (SRI) and VirTra (VTSI) emerge as winning picks.
12/06 21:00 EST - businesswire.com
ORGANOGENESIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Organogenesis Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Organogenesis Holdings, Inc. (NASDAQ: ORGO) on behalf of long-term stockholders following a class action complaint that was filed against Organogenesis on December 10, 2021 with a Class Period from March 17, 2021 to October 11, 2021. Our investigation concerns whether the board of directors of Organogenesis have breached their fiduciary dutie.
ORGANOGENESIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Organogenesis Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Organogenesis Holdings, Inc. (NASDAQ: ORGO) on behalf of long-term stockholders following a class action complaint that was filed against Organogenesis on December 10, 2021 with a Class Period from March 17, 2021 to October 11, 2021. Our investigation concerns whether the board of directors of Organogenesis have breached their fiduciary dutie.
11/30 10:32 EST - zacks.com
Here Is Why Bargain Hunters Would Love Fast-paced Mover Organogenesis (ORGO)
Organogenesis (ORGO) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Here Is Why Bargain Hunters Would Love Fast-paced Mover Organogenesis (ORGO)
Organogenesis (ORGO) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
11/09 22:16 EST - seekingalpha.com
Organogenesis Holdings, Inc. (ORGO) Q3 2023 Earnings Call Transcript
Organogenesis Holdings, Inc. (NASDAQ:ORGO ) Q3 2023 Earnings Conference Call November 9, 2023 5:00 PM ET Company Participants Gary Gillheeney - President, CEO & Chair David Francisco - CFO Conference Call Participants Ryan Zimmerman - BTIG Operator Welcome, ladies and gentlemen, to the Third Quarter of Fiscal Year 2023 Earnings Conference Call for Organogenesis Holdings Inc. [Operator Instructions]. Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly.
Organogenesis Holdings, Inc. (ORGO) Q3 2023 Earnings Call Transcript
Organogenesis Holdings, Inc. (NASDAQ:ORGO ) Q3 2023 Earnings Conference Call November 9, 2023 5:00 PM ET Company Participants Gary Gillheeney - President, CEO & Chair David Francisco - CFO Conference Call Participants Ryan Zimmerman - BTIG Operator Welcome, ladies and gentlemen, to the Third Quarter of Fiscal Year 2023 Earnings Conference Call for Organogenesis Holdings Inc. [Operator Instructions]. Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly.
11/09 16:05 EST - globenewswire.com
Organogenesis Holdings Inc. Reports Third Quarter 2023 Financial Results
CANTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the third quarter ended September 30th, 2023.
Organogenesis Holdings Inc. Reports Third Quarter 2023 Financial Results
CANTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the third quarter ended September 30th, 2023.